


The background of the slide features a grayscale image of a complex antibody protein structure, which is a Y-shaped molecule composed of multiple polypeptide chains. Overlaid on this are several white, five-pointed stars arranged in a circular pattern, reminiscent of the European Union flag. The overall aesthetic is scientific and professional.

FCF Fox Corporate Finance | FCF Healthcare & Life Sciences  
**Healthcare & Life Sciences Venture Capital Monitor – Europe**

*November 2023*

*Antibody*

**FCF HEALTHCARE & LIFE SCIENCES  
OVERVIEW**



## Overview



### Focus on Biotech, MedTech and HealthTech

We advise innovative companies on arranging, structuring and placing equity, debt, and licensing transactions in a holistic financing approach



### Focus Areas

FCF advises on the following transaction types:



**FCF  
Healthcare  
& Life Sciences**  
*advises leading  
HC & LS companies  
in Europe in financing  
transactions*

*Over EUR 2bn  
Healthcare  
& Life Sciences  
transaction  
volume*  
*(Professionals and  
Advisors)*

*Healthcare &  
Life Sciences  
Team of  
>12*

*Over 100 years  
in aggregated  
Healthcare &  
Life Sciences  
experience*

*Access to  
> 1,500  
international  
investors*

**Company  
Valuation**  
*in partnership with  
BioScience  
Valuation GmbH*

**China Licensing**  
*in partnership with  
YAFO Capital*

**Leading  
EIB advisor  
in Europe**

*Over 80  
completed  
Healthcare & Life  
Sciences  
transactions  
(Professionals and  
Advisors)*

*8 regularly  
published  
Healthcare &  
Life Sciences  
reports*

## Healthcare & Life Sciences Team



**Dr. Alexandra  
Goll**  
*Advisor –  
Venture Capital*



**Dr. Axel Polack**  
*Advisor – Science &  
Technology*



**Claus Schalper**  
*Advisor –  
Corporate Affairs*



**Mathias  
Klozenbuecher**  
*Head of Healthcare & Life  
Sciences*



**Johannes Link**  
*Healthcare & Life Sciences  
Banking – Europe*



**Marco Vollnhals**  
*Healthcare & Life Sciences  
Banking – Europe*



**Enno Spillner**  
*Advisor –  
Capital Markets*



**Dr. Joachim  
M. Greuel**  
*Advisor – Valuations*



**Prof. Dr.  
Horst Domdey**  
*Advisor – Science &  
Technology*



**Zaid Maleh**  
*Healthcare & Life Sciences  
Banking – Dubai*



**Sean Jian, CFA**  
*Healthcare & Life Sciences  
Banking – China*



## Services

- ✓ Integrated Financial Modelling
- ✓ Investor / IR Roadshow
- ✓ Investor Screening
- ✓ Equity & Debt Fundraising
- ✓ Management Presentation
- ✓ Term Sheet Negotiation
- ✓ Post-Transaction Support
- ✓ Life Science Advisory Board
- ✓ Due Diligence Support
- ✓ Closing Assistance
- ✓ Financing Strategy Advisory
- ✓ IPO Execution Support

*(extract from service portfolio)*

## Our capital markets research feeds our proprietary investor database

### Data Collection

#### Healthcare & Life Sciences

##### Venture Capital Monitor – EU



- *Venture Capital*
- *Healthcare & Life Sciences*
- *Focus on Europe*

##### Healthcare & Life Sciences Venture Capital Report



- *Venture Capital*
- *Healthcare & Life Sciences*
- *Focus on Europe and the US*

##### Biotech Public Equity Monitor



- *Public Equity*
- *Biotech*
- *Focus on Europe*

##### Healthcare & Life Sciences IPO Report



- *IPOs*
- *Healthcare & Life Sciences*
- *Focus on Europe and the US*

##### Biotech Venture Capital Monitor – US



- *Venture Capital*
- *Life Sciences*
- *Focus on the US*

##### Biotech Licensing Monitor – China



- *Licensing*
- *Biotech*
- *Focus on Europe and Chinese licensors*

##### MedTech Public Equity Monitor



- *Public Equity*
- *MedTech*
- *Focus on Europe*

##### Healthcare & Life Sciences SPAC Monitor




- *SPACs*
- *Life Sciences*
- *Focus on US / Europe and US SPACs*

### Market Monitoring

#### Data Processing

- *Transaction data*
- *Investment preferences*




#### Constant Data Enrichment

- *Ongoing investor communication*
- *Data validation*

#### Proprietary Investor Database

- *Most comprehensive database*
- *> 1,300,000 data points*



#### Data-driven Investor Selection



- *Intelligent search algorithms*
- *Big data sequencing*

# Executive Summary

*The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is a monthly published overview focusing on the venture capital financing environment in the Biotech, Pharmaceutical, MedTech and HealthTech segments, and can be used as a quick reference for investors, corporates and professionals*

*More advanced, detailed and / or customized reports are available upon request*

## **FCF Healthcare & Life Sciences Venture Capital Monitor - Europe**

is a monthly published overview of Biotech, Pharmaceutical, MedTech and HealthTech companies, displaying venture capital financing trends in the European healthcare & life science industry

### **Scope**

The selection of companies is based on the following criteria:

- Focus on transactions with European headquartered healthcare & life science companies and available deal volume
- Companies operating in the Biotech, Pharmaceutical, MedTech, HealthTech, Services or other life science related sectors
- The Biotech sector is further divided into the following therapy areas / indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

*To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information*

### **Recipients**

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe targets the following recipients:

- Corporates / Executives
- Institutional investors
- Private equity investors
- Venture capital investors
- Family Offices / High-net-worth individuals
- Advisors

### **Availability**

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is available on FCF's website at "<https://www-fcf-de/de/life-sciences/>"

### **Data**

All input data is provided by Pitchbook and is not independently verified by FCF- Ratio and multiple calculations are driven based on the input data available- For additional information and disclaimer, please refer to the last page

*If you have questions, comments or ideas, please do not hesitate to contact us*


**EUROPEAN VENTURE CAPITAL TRANSACTIONS  
IN HEALTHCARE & LIFE SCIENCES**

NOVEMBER 2023




### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	UK	208	C
3	Distalmotion	CH	142	F
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	FR	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	230	55
2	Forbion	DK	172	12
3	Jeito	FR	168	12
4	Revival Healthcare Capital	US	142	2
5	Gilde Healthcare Partners	DK	137	10

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
1	30/11/2023	Milbotix	GBR	MedTech	Monitoring Device / On market	Developer of a smart sock designed to improve access to psychological or physical assistance for people with unmet needs related to a health condition.	-	< 1	< 1	The company raised GBP 343,043 of venture funding on November 30, 2023, putting the company's pre-money valuation at GBP 2.23 million.
2	29/11/2023	Oncovita	FRA	Biotech / Pharma	Oncology / Pre-clinic	Operator of a biotech firm intended to serve for the development of life-saving new treatments, especially for cancer treatment therapy.	-	4	4	The company raised EUR 3.5 million of venture funding on November 29, 2023. The funds will be used to enable the company to accelerate the preclinical and clinical development of MVdeltaC.
3	28/11/2023	KARDI AI	CZE	MedTech	Monitoring Device / On market	Developer of a heart monitoring device designed to offer medical-grade cardiac home monitoring by utilizing artificial intelligence.	-	2	2	The company raised EUR 1.5 million of venture funding on November 28, 2023.
4	27/11/2023	1nhaler	GBR	MedTech	Drug Delivery Platform / Undisclosed	Developer of a technology platform intended to assist with inhalable dry powder medications.	-	2	2	The company raised GBP 2 million of venture funding on November 27, 2023, putting the company's pre-money valuation at GBP 6.27 million. The funds will be used to work with innovative companies around the world, allowing them to bring new and existing drugs to patients in a more affordable way.
5	24/11/2023	DocCity	FRA	Healthcare Services	Other / On market	Provider of health space services intended to offer healthcare professionals a real quality of life at work.	-	30	45	The company raised EUR 30 million of venture funding on November 24, 2023.
6	24/11/2023	Floy	DEU	HealthTech	Diagnostic Software / On market	Developer of an artificial intelligence-driven software designed to support radiologists in detecting complex and hard-to-identify diseases.	-	5	8	The company raised EUR 5.4 million of venture funding on November 24, 2023. The funds will be used to accelerate its expansion.
7	23/11/2023	Cradle Bio	NLD	Biotech / Pharma	Discovery Platform / On market	Developer of an algorithm and artificial intelligence tool designed to help biologists design improved proteins.	A	22	28	The company raised \$24 million of Series A venture funding on November 23, 2023. The funds will be used to speed up the company's progress, increase its machine studying and biotech crew and proceed to spend money on its product growth and gross sales capabilities.
8	23/11/2023	Aelius Biotech	GBR	Healthcare Services	Other / On market	Developer of a model gut system intended to help healthcare industry participants simulate digestion, mucus permeation, and epithelial absorption in a single system.	-	1	1	The company raised GBP 1.25 million of venture funding on November 23, 2023. The funds will be used to meet demand by relocating from the university into laboratories in Newcastle, and expand its five-strong team with the creation of ten new jobs in the next two years.

Source: PitchBook as of 07-12-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

# European Venture Capital Transactions in Healthcare & Life Sciences


## November 2023

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3		683	E
2	Apollo Therapeutics		208	C
3	Distalmotion		142	F
4	CMR Surgical		142	D
5	Amolyt Pharma		130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund		230	55
2	Forbion		172	12
3	Jeito		168	12
4	Revival Healthcare Capital		142	2
5	Gilde Healthcare Partners		137	10

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Volume (EURm)	Total Raised (EURm)	Deal Synopsis
9	23/11/2023	LAYCO	NLD	MedTech	Medical Devices / On market	Developer of reusable medical devices to enhance healthcare accessibility and minimize the environmental footprint of the healthcare sector.	-	< 1	< 1	The company raised EUR 300,000 of venture funding in the form of convertible debt on November 23, 2023. The funds will be used to advance the development and conduct testing of vela in a practical environment, with specific emphasis on trials at the Amsterdam UMC.
10	22/11/2023	Quotient Therapeutics	GBR	Biotech / Pharma	Drug Development / On market	Developer of a platform intended to create transformative therapeutics with naturally selected targets.	-	47	47	The company raised \$50 million of venture funding on November 22, 2023. The funds will be used to advance development of its platform.
11	22/11/2023	OnDosis	SWE	MedTech	Other / On market	Developer of a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines.	-	6	158	The company raised SEK 72 million of venture funding on November 22, 2023.
12	22/11/2023	Linio Biotech	FIN	Biotech / Pharma	Dermatology / On market	Developer of cell-free tissue technology designed for tissue regeneration to be simple, sustainable, and accessible.	-	4	8	The company raised EUR 4.2 million of venture funding on November 22, 2023. The funds will be used to expand the availability of the company's Tience® products and treatments.
13	22/11/2023	Callyope	FRA	MedTech	Monitoring Device / On market	Operator of a speech-based technology platform intended to monitor brain functionality.	-	2	2	The company raised EUR 2.2 million of venture funding on November 22, 2023.
14	22/11/2023	Nanological	ESP	MedTech	Infectious Diseases / Undisclosed	Operator of a deep tech company intended to combine science and technology for the development of state-of-the-art medical devices.	-	< 1	< 1	The company raised EUR 600,000 of venture funding on November 22, 2023.
15	21/11/2023	Bioxodes	BEL	Biotech / Pharma	Other / Phase I	Operator of a clinical-stage biopharmaceutical company intended to help thrombosis and neuroinflammation in hemorrhagic stroke patients.	A	9	24	The company raised EUR 8.53 million of Series A venture funding on November 21, 2023, putting the company's pre-money valuation at EUR 21.25 million. The funds will be used to continue clinical development of drug candidate for patients with intracerebral hemorrhage.
16	21/11/2023	Doccla	GBR	Healthcare Services	Virtual Ward Services / On Market	Provider of virtual ward services intended to shift patient care from hospitals to the home.	-	6	30	The company raised GBP 5 million of venture funding on November 21, 2023. The funds will be used for expansion in Europe with a focus on Germany market.

Source: PitchBook as of 07-12-2023; FCF Equity Research


Note: All volumes in EURm; financing rounds without deal values are excluded

<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)




### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	UK	208	C
3	Distalmotion	CH	142	F
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	FR	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	230	55
2	Forbion	DK	172	12
3	Jeito	FR	168	12
4	Revival Healthcare Capital	US	142	2
5	Gilde Healthcare Partners	DK	137	10

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Volume (EURm)	Total Raised (EURm)	Deal Synopsis
17	21/11/2023	respiQ	NLD	MedTech	Diagnostic Device / On market	Developer of a healthcare medical device designed to provide accurate, non-invasive, and affordable technology for early detection of health issues.	-	4	< 1	The company received EUR 4 million in funding on November 21, 2023. The funds will be used by the company to accelerate the development and miniaturization of its breath diagnostics technology, enhancing non-invasive remote patient monitoring.
18	21/11/2023	Textray	SWE	MedTech	Other / On market	Developer of radiation protection textile designed for medical practitioners using X-rays in surgical interventions.	-	4	4	The company raised SEK 45 million of venture funding on November 21, 2023.
19	21/11/2023	Biped	CHE	MedTech	Ophthalmology / On market	Developer of a smart harness designed to help blind and visually impaired people.	-	1	2	The company raised CHF 1.2 million of venture funding on November 21, 2023. The funds will be used to enter the US market and expand the company's presence across Europe to scale its operations, enhance its technology, and reach more individuals.
20	20/11/2023	Plumm	GBR	HealthTech	Mental Health Platform / On market	Operator of an online mental health care platform designed for mental well-being which connects clients with certified and accredited therapists globally.	-	3	3	The company raised GBP 2.2 million of venture funding on November 20, 2023. The funds will be used to grow the company's partnerships, sales and marketing teams, and expanding operations within the UK and internationally in the EU, Middle East and US.
21	17/11/2023	Umecrine Cognition	SWE	Biotech / Pharma	Central Nervous System / Phase II	Developer of pharmaceutical products designed to treat cognitive neurological disorders.	-	3	31	The company raised SEK 30.4 million of venture funding in the form of convertible debt on November 17, 2023.
22	16/11/2023	Pregnoia	CHE	MedTech	Women's Health / On market	Developer of a pregnancy diagnostic tool designed to detect the early changes in the cervix.	-	2	9	The company raised CHF 2.22 million of venture funding on November 16, 2023, putting the company's pre-money valuation at CHF 14.17 million. The funds will be used for the costs of the ongoing clinical studies as well as the processing of the data and is also developing a roadmap to obtain approval from the FDA (Food and Drug Administration of the USA) of the company diagnostic system for the US to maintain the market.
23	15/11/2023	NMD Pharma	DNK	Biotech / Pharma	Neuromuscular Disorders / Phase II	Operator of a clinical-stage biotech company intended to design drugs and therapeutics for the treatment of neuromuscular disorders.	B	75	180	The company raised EUR 75 million of Series B venture funding on November 15, 2023. The funds will be used to expand NMD Pharma's clinical and commercial operations in Denmark and in the US.
24	15/11/2023	T-Therapeutics	GBR	Biotech / Pharma	Discovery Platform / On market	Operator of a biopharmaceutical company developing engineered T-cell therapies intended to treat chronic and infectious diseases.	A	55	72	The company raised GBP 48 million of venture funding on November 15, 2023. The funds will be used to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.


Source: PitchBook as of 07-12-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	UK	208	C
3	Distalmotion	CH	142	F
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	FR	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	230	55
2	Forbion	DK	172	12
3	Jeito	FR	168	12
4	Revival Healthcare Capital	US	142	2
5	Gilde Healthcare Partners	DK	137	10

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Volume (EURm)	Total Raised (EURm)	Deal Synopsis
25	15/11/2023	Aufbau Holdings	IRL	Biotech / Pharma	Other / Undisclosed	Operator of a biotechnology company intended to develop novel diagnostic and therapeutics for ophthalmic diseases and cancer.	-	1	14	The company raised \$1.09 million of venture funding on November 15, 2023.
26	14/11/2023	EyeBio	GBR	Biotech / Pharma	Ophthalmology / Phase I	Developer of a vision therapy intended to protect, restore and improve vision.	A	122	123	The company raised \$130 million of Series A venture funding on November 14, 2023. The funds will be used to accelerate the Company's clinical development program and further build out its innovative retina pipeline.
27	14/11/2023	Nouscom	CHE	Biotech / Pharma	Oncology / Phase II	Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer.	C	68	122	The company raised EUR 67.5 million of Series C venture funding on November 14, 2023. The funds will be used to continue advancing and expanding the company's wholly-owned clinical pipeline to achieve multiple clinical value catalysts.
28	14/11/2023	tech2People	AUT	MedTech	Physiotherapy / On market	Developer of robotic neurotherapy systems intended to offer conventional physiotherapy from a single source.	-	< 1	5	The company raised an estimated EUR 800,000 of venture funding on November 14, 2023. The funds will be used to expand the company's neuro, physio, and ergotherapy services and to pursue its mission to improve the quality of life of people with neurological diseases and physical disabilities.
29	13/11/2023	VectorY Therapeutics	NLD	Biotech / Pharma	Other / Pre-clinic	Developer of a medical platform designed to bring novel therapies to patients worldwide.	A	129	160	The company raised EUR 129 million of Series A venture funding on November 13, 2023. The funds will be used to support the clinical development of VTX-002, its lead vectorized antibody program targeting TDP-43 for the treatment of ALS and it will also accelerate the development of its vectorized antibody platform and additional pipeline programs targeting proteinopathies causing other neurodegenerative diseases.
30	13/11/2023	ViaNautis	GBR	Biotech / Pharma	Central Nervous System / Discovery	Developer of nanoparticle technology designed to offer self-assembly polymers for intracellular delivery.	A	24	27	The company raised \$25 million of Series A venture funding on November 13, 2023. The funds will be used to drive the next generation of genetic nanomedicines and to fuel the rapid development of products using the polyNaut platform, expand the scientific and management teams, and establish industry-leading laboratory facilities.
31	13/11/2023	BioSerenity	FRA	MedTech	Chronic Diseases / On market	Developer of digitally connected devices intended to optimize the patient pathways in several chronic diseases.	-	23	105	The company raised \$24 million of venture funding on November 13, 2023. The funds will be used to accelerate the international development of company's activities by building on its two main markets - France and the United States, and focusing on Europe and to deploy powerful AI to help doctors with their diagnoses.
32	13/11/2023	Aether Biomedical	POL	MedTech	Other / On market	Developer of medical robotic arms designed to build bionic limbs for upper limb amputees using biosignal processing.	A	5	10	The company raised \$5.8 million of Series A venture funding on November 13, 2023. The funds will be used to improve the company's manufacturing process.


Source: PitchBook as of 07-12-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3		683	E
2	Apollo Therapeutics		208	C
3	Distalmotion		142	F
4	CMR Surgical		142	D
5	Amolyt Pharma		130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund		230	55
2	Forbion		172	12
3	Jeito		168	12
4	Revival Healthcare Capital		142	2
5	Gilde Healthcare Partners		137	10

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
33	10/11/2023	Neogap	SWE	Biotech / Pharma	Oncology / Phase I	Developer of personalized cancer immunotherapy designed to precisely target and eliminate cancer.	-	5	10	The company raised SEK 54 million of venture funding on November 10, 2023.
34	10/11/2023	Neogap	SWE	Biotech / Pharma	Oncology / Phase I	Developer of personalized cancer immunotherapy designed to precisely target and eliminate cancer.	-	2	10	The company received SEK 29 million in funding in the form of grant on November 10, 2023.
35	10/11/2023	PeptiGen	GBR	Biotech / Pharma	Discovery Platform / Undisclosed	Developer of an innovative biotech platform designed to generate unique and patentable peptide structures.	-	< 1	< 1	The company raised RUB 5.5 million of venture funding on November 10, 2023. The funds will be used to strengthen the company's market position and update its portfolio.
36	09/11/2023	doctory	DEU	HealthTech	Patient Management Platform / On market	Developer of a medical practice platform designed for doctors to manage the whole process in one system.	A	17	24	The company raised EUR 16.6 million of Series A venture funding on November 9, 2023. The funds will be used further to accelerate the company's growth in the German market while it seeks to deliver new features and functionality aimed at reducing administrative costs and saving time to make work for healthcare professionals easier and faster and build out its commercial team.
37	09/11/2023	Biosency	FRA	MedTech	Medical Device / On Market	Developer of a medical device designed to monitor and prevent respiratory failures for patients.	-	7	15	The company raised EUR 7 million of venture funding on November 9, 2023.
38	08/11/2023	Amyl Therapeutics	BEL	MedTech	Hormonal Disorders / On market	Operator of a biotechnology company intended to develop therapeutics for the treatment of all forms of amyloidosis.	A	29	14	The company raised EUR 29.4 million through a combination of equity and grant on November 8, 2023. The funds will be used to accelerate the development of the company's preclinical pipeline to treat neurodegenerative diseases and AL amyloidosis.
39	08/11/2023	Letoon Holding	GBR	Biotech / Pharma	Other / On market	Manufacturer and provider of medicinal oil intended to cater to people in London, England.	-	23	23	The company raised GBP 20 million of venture funding on November 8, 2023.
40	08/11/2023	Anima (Enterprise Systems Healthcare)	GBR	HealthTech	Patient Management Platform / On market	Operator of a healthcare management platform intended to help healthcare providers to manage patient care efficiently.	-	14	16	The company raised \$14.49 million of venture funding on November 8, 2023.


Source: PitchBook as of 07-12-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	UK	208	C
3	Distalmotion	CH	142	F
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	FR	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	230	55
2	Forbion	NL	172	12
3	Jeito	FR	168	12
4	Revival Healthcare Capital	US	142	2
5	Gilde Healthcare Partners	NL	137	10

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
41	08/11/2023	CoMind (Decision/Risk Analysis)	GBR	MedTech	Central Nervous System / Developing	Developer of a neuro-sensing technology designed to positively change how humans interact with machines.	-	11	24	The company raised GBP 9.75 million of venture funding on November 8, 2023, putting the company's pre-money valuation at GBP 26.42 million.
42	08/11/2023	Octarine Bio	DNK	Biotech / Pharma	Other / Pre-clinic	Developer of cannabinoids and psilocybin derivatives intended to improve the health and well-being of people.	-	4	10	The company raised EUR 4.35 million of venture funding on November 8, 2023. The funds will be used to accelerate and scale the company's portfolio.
43	08/11/2023	Soundsafe Care	ITA	MedTech	Surgical Device / Pre-clinic	Developer of a medical technology designed to combine ultrasound and robotics to disrupt the conventional ways of performing surgery.	-	2	2	The company raised EUR 1.75 million of venture funding on November 8, 2023.
44	08/11/2023	AI Sight	GBR	HealthTech	Ophthalmology / Undisclosed	Developer of AI diabetic retinal screening system intended to provide WHO-recommended diabetic eye screening services.	-	< 1	< 1	The company raised GBP 301,964 of venture funding on November 8, 2023, putting the company's pre-money valuation at GBP 3 million.
45	07/11/2023	Kynexis	NLD	Biotech / Pharma	Central Nervous System / Undisclosed	Developer of a precision medicine intended for the treatment of cognitive impairment associated with schizophrenia.	A	57	57	The company raised EUR 57 million of Series A venture funding on November 7, 2023. The funds will be used to test ex-Mitsubishi Tanabe drug for schizophrenia.
46	06/11/2023	VUS Diagnostics	NLD	Biotech / Pharma	Oncology / On market	Operator of a genetic-focused precision diagnostic company intended to help improve how diagnostics can guide treatment approaches for cancer and other genetic diseases.	-	< 1	< 1	The company raised EUR 300,000 of venture funding in the form of a convertible loan on November 6, 2023.
47	06/11/2023	XENA Dx	DEU	MedTech	Women's Health / Undisclosed	Developer of a non-invasive diagnostic software designed to diagnose endometriosis patients.	-	< 1	< 1	The company received \$120,000 in funding on November 6, 2023, putting the company's pre-money valuation at \$1.88 million.
48	02/11/2023	Memo Therapeutics	CHE	Biotech / Pharma	Infectious Diseases / Phase II	Developer of antibody discovery and immune repertoire analysis platform designed to transform the lives of patients with virus infections and cancer.	C	26	68	The company raised CHF 25 million of Series C venture funding on November 2, 2023. The funds will be used to support the completion of a Phase II trial of AntiBKV and to prepare the manufacturing of the drug for Phase III.


Source: PitchBook as of 07-12-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	UK	208	C
3	Distalmotion	CH	142	F
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	FR	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	230	55
2	Forbion	DK	172	12
3	Jeito	FR	168	12
4	Revival Healthcare Capital	US	142	2
5	Gilde Healthcare Partners	DK	137	10

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series (EURm)	Total Volume Raised (EURm)	Deal Synopsis	
49	02/11/2023	HeartBeat.bio	AUT	HealthTech	Diagnostics Application / On market	Operator of a drug discovery company intended to focus on the development of a fully human high-throughput three-dimensional screening for heart failure using the world's first self-organizing cardiac organoids.	-	5	10	The company raised EUR 4.5 million of venture funding on November 2, 2023. The funds will be used for the completion of a ready-to-use, fully integrated, automated, high-throughput Cardioid Drug Discovery Platform for proprietary and collaborative drug discovery programs in indications with a high medical need such as drug-induced and genetic cardiomyopathies as well as myocardial infarction and fibrosis.
50	01/11/2023	Frieda Health	DEU	HealthTech	Women's Health / On market	Developer of a health platform intended to provide menopause support.	-	2	2	The company raised €2.5 million venture funding in approximately November 2023.
51	01/11/2023	Kiplin	FRA	HealthTech	Federated Learning Software / On market	Developer of fun health prevention program platform designed to use gamification to facilitate lifestyle changes in physical activity.	-	< 1	5	The company raised EUR 359,473 of equity crowdfunding in approximately November 2023.
52	01/11/2023	Kinvent	FRA	MedTech	Monitoring Device / On market	Manufacturer of training devices intended to monitor athletic movements.	-	< 1	7	The company received EUR 50,000 in funding in approximately November 2023.
53	01/11/2023	Callisia	ITA	MedTech	Monitoring Device / Developing	Developer of a wearable patient monitoring device intended to collect patient data for real-time visualization and data analysis.	-	< 1	< 1	The company received EUR 30,000 in funding in November 2023, putting the company's pre-money valuation at EUR 570,000.

Source: PitchBook as of 07-12-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

# Contact Details & Disclaimer



## FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany  
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299  
info@fcf.de ▪ www.fcf.de

### Arno Fuchs

*Chief Executive Officer*

P: +49 (89) 206 0409-100  
M: +49 (172) 863 6777  
arno.fuchs@fcf.de

### Mathias Klozenbuecher

*Managing Director*

P: +49 (89) 2060 409-123  
M: +49 (174) 301 1846  
mathias.klozenbuecher@fcf.de

### Johannes Link

*Associate*

P: +49 (89) 206 0409-150  
M: +49 (172) 839 5746  
johannes.link@fcf.de

### Marco Vollnhals

*Intern*

P: +49 (89) 206 0409-127  
marco.vollnhals@fcf.de

## DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2023



THE FINANCING SPECIALIST